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The interaction of 784 intergenic (ig-miRNA), 686 intronic (in-miRNA) and 49 exonic miRNAs (ex-miRNA) 
with mRNAs of 51 oncogenes coding in-miRNAs was investigated. Out of the studied genes, 44 were 
targets for 94 ig-miRNAs, 29 were targets for 44 in-miRNAs and 7 were targets for 7 ex-miRNAs. The 
density of miRNA binding sites was higher in 5'-untranslated regions than it was in coding sequences 
and 3'-untranslated regions. Three types of miRNA interaction with mRNA were revealed: 5'-dominant 
canonical, 3'-compensatory and complementary types. In-miRNAs do not interact with mRNAs of host 
genes (where in-miRNA is encoded). Linkage between some mRNAs of genes encodes in-miRNAs via 
other in-miRNAs was revealed. These data promote the understanding of interaction mechanism of 
miRNA with mRNA genes participating in gastrointestinal and breast cancers. 
 
Key words: Intergenic miRNA, intronic miRNA, exonic miRNA, mRNA, 5'-untranslated region, coding 
sequences, 3'-untranslated region, human, oncogene. 
 
 
INTRODUCTION 
 
MicroRNAs (miRNA) are non-protein coding RNA 
sequences that have length of about 22 nucleotides (nt). 
miRNA are evolutionary conservative in many organisms 
and accomplishes important regulatory function (Ibanez-
Ventoso et al., 2008). The binding miRNA with mRNA 
leads to specific splitting, deadenylation or translation 
repression (Pillai et al., 2007). miRNA genes can be 
encoded in the intergenic or intragenic regions. Intragenic 
miRNAs are situated within intron or exon of their host 
genes (Kim and Kim, 2007). Some of the miRNAs are 
found on bonder of exon and intron (Rodriguez et al., 
2004). The number of miRNA is considerably enlarged 
due to new methods of search and comparison of targets. 
MiRNAs regulate translation of about 60% of all human 
protein-coding genes (Friedman et al., 2009). mRNA can 
have some binding sites with one or with several 
miRNAs. Hence, the  influence of  miRNA on  inhibition of  
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mRNA translation becomes greater (Baek et al., 2008; 
Selbach et al., 2008; Grimson et al., 2007). Deregulation 
in miRNA expression is one main cause of cancer 
(Hamano et al., 2011), cardiovascular (Small et al., 2010) 
and other diseases (Jiang et al., 2010). Aberrant miRNA 
expression has been well characterized in different 
oncology diseases and their progression (Cortez et al., 
2012). Expression of some miRNAs is changed in 
development esophageal cancer (Fang et al., 2012), 
gastric cancer (Lu et al., 2011), colorectal cancer 
(Hamfjord et al., 2012), breast cancer (Hafez et al., 2012; 
Hanna et al., 2012) and other cancer types. 
Many programs for miRNA binding sites prediction 
have been developed (Sethupathy et al., 2006). A search 
for miRNA sites are based on revealing of complementary 
seed (part of 5'-end miRNA site). The programs have 
algorithms for identification of RNA seed with length from 
6 to 8 nt (Friedman et al., 2009; Lewis et al., 2003). Site 
searching for only short seed leads to the prediction of 
considerable quantity of false sites. Some programs take 
the advantage of seed conservation to assess site 
specificity.  However,  there   are   many  nonconservative  
 
 
 
 
seed-site of miRNAs already known (Baek et al., 2008). 
Some programs predict not perfectly complementary 
seed in the presence of 3'-compensatory site (Farh et al., 
2005).  
Most programs allow search for sites only in 3'-
untranslated regions (3'UTR) (Maragkakis et al., 2011). It 
has been shown that miRNA sites may also occur in open 
reading frame (ORF) (Baek et al., 2008). Many 
researchers consider that miRNAs interact with mRNAs 
only in 3'UTR (Delay et al., 2011; Iorio et al., 2009; Isik et 
al., 2010; Kruger and Rehmsmeier, 2006; Satoh and 
Tabunoki, 2011), however, publications which describe 
miRNAs binding to mRNAs in 5'-untranslated regions 
(5'UTR) and coding sequences (CDS) are known 
(Duursma et al., 2008; Elcheva et al., 2009; Kulkarni et 
al., 2011; Moretti et al., 2010; Tsai et al., 2009).  
MiRNA binding sites, predicted by computer method, 
which is founded by obligatory complementarity of 5'-
seed region, are checked experimentally. However, some 
other miRNA binding sites, based on 3'-compensatory 
type, are not predicted by such method, but they are 
identified in experiments (Qin et al., 2010; Shirdel et al., 
2011).  
Program RNAhybrid (http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/) relies on thermodynamics and 
allows the search for 5'-dominant initial, 5'-seed-dominant 
and 3'-compensatory types of target sites (Garcna et al., 
2011). An accurate identification of miRNA:mRNA pairs 
should promote considerable development of diagnostic 
methods of various cancer diseases. 
The present research aimed to reveal miRNA binding 
sites with various parts of mRNA (5'UTR, CDS and 
3'UTR) and defined nucleotide interaction features of 
miRNA:mRNA complexes. This study was realized for 
miRNAs involved in cancer and should be extended to 
other genes.  
 
 
MATERIALS AND METHODS 
 
Nucleotide sequences of miRNAs and their precursors were found 
from miRBase (http://www.mirbase.org). Nucleotide sequences 
mRNAs of all genes (Homo sapiens, Genome build 37.2.) were 
obtained from GenBank (http://www.ncbi.nlm.nih.gov). Then, 
miRNAFinder 2.2 (https://sites.google.com/site/malaheenee/home) 
was used to find miRNA origins (intergenic, exonic or intronic). A 
literature review of genes coding intronic miRNAs led to 51 
oncogenes (Supplementary Table 1) that encode proteins 
participating in gastrointestinal and breast cancer. This information 
was collected according to articles from US National Library of 
Medicine, National Institutes of Health PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed). 
RNAhybrid 2.1 was run for all pairs (miRNA:mRNA complexes) 
and provided positions of potential binding sites miRNAs in mRNAs, 
free energy of miRNA binding sites (ΔG) and scheme of their 
interaction.  
The script E-RNAhybrid 
(https://sites.google.com/site/malaheenee/home) computes the ratio 
ΔG/ΔGm, p-value, equalizing coefficient and type of corresponding 
regions (5'UTR, CDS or 3'UTR), where miRNA site disposes. To 
achieve this, a  quantitative  criterion  was  defined. A  ratio ΔG/ΔGm 
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was measured as percentage, where ΔGm equals binding energy 
for miRNA with perfectly complementary nucleotide sequence 
computed. Number of binding sites in 5'UTR, CDS and 3'UTR was 
calculated as the number of sites (s) divided to nucleotide length (l) 
of this region and multiplied by 10
3
 (s/l), that is, calculation per 1000 
nucleotides. Significance degree (p-value) was estimated, that 
relies on ΔG and its standard deviation. The binding sites had ratio 
ΔG/ΔGm that equals or more than 80%.  
 
 
RESULTS  
 
784 intergenic, 686 intronic and 49 exonic miRNAs were 
found by program miRNAFinder 2.2. 471 genes encode 
686 intronic pre-miRNAs. In these genes are situated one 
or more in-miRNAs. Among them, only 51 genes encode 
proteins participating in the development of 
gastrointestinal and breast cancer according to literature 
reviewed of all these genes (Supplementary Table 1). 
Interaction of all studied miRNAs with mRNAs of 51 
oncogenes was investigated by script E-RNAhybrid. The 
obtained results show a linkage between several mRNA 
of genes encoding in-miRNAs via other in-miRNAs (these 
miRNAs localize in genes that are not targets). Similar 
results can be found on three types of miRNA. It was 
established that all mRNA regions (5'UTR, CDS and 
3'UTR) have miRNA binding sites. The density of sites 
and their distribution on these mRNA regions was 
revealed. Complementary type of miRNA binding sites 
was found. 
 
 
Interaction of intergenic miRNA with mRNA 
oncogenes coding in-miRNA 
 
Binding sites of 784 ig-miRNAs with 51 mRNAs were 
studied. Shares of binding sites for ig-miRNAs were 16.7, 
57.3 and 26.0% in 5'UTR, CDS, 3'UTR of mRNAs, 
respectively. However, the density of binding sites in 
5'UTR, CDS and 3'UTR mRNA was 2.32, 0.88 and 0.80 
s/l, respectively, for these genes. Ig-miRNA binding sites 
with the best characteristics are represented in Tables 1 
to 3. 5'UTR of some mRNAs can have several miRNA 
binding sites despite their short length (Table 1). For 
example, NR2F2 gene had four binding sites; EPCAM, 
HNF4A and SLIT3 genes have three sites and EGFL7, 
HDAC4, LRP1 genes have two sites in 5'UTR. Several 
miRNAs have some targets of studied genes. MiR-4472 
had binding sites in CDS of 7 genes (AATK, HDAC4, 
LRP1, MAP2K4, NOTCH1, PTPRJ and SLIT3), where 
LRP1 gene has three sites and NOTCH1 gene has two 
sites (Table 2). MiR-4456, miR-4455 and miR-4711-3p 
had binding sites in CDS six, five and four mRNAs 
accordingly. These miRNAs are important as they have 
binding sites with many mRNAs of studied genes. 
Characteristics of site location in 3'UTR were the same 
as in 5'UTR and CDS (Table 3). BRE, IGF1R and 
MRE11A genes were targets for miR-4456; BBC3 and 
NOTCH1 genes were targets for miR-1587. mRNA BBC3 
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Table 1. Positions of ig-miRNA binding sites in 5'UTR mRNA. 
 
Target gene miRNA Position (nt)  Target gene miRNA Position (nt)  Target gene miRNA Position (nt) 
AATK miR-4417 45  HDAC4 miR-1268 80  NR2F2 miR-4253 537 
ATF2 miR-4319 63  HNF4A miR-302f 71  NR2F2 miR-4787-5p 1152 
BRE miR-4455 39  HNF4A miR-1279 1  PRKG1 miR-1268 142 
DCC miR-568 524  HNF4A miR-4307 76  PTK2 miR-3676 22 
DTL miR-4309 44  HUWE1 miR-4266 134  PTPRJ miR-3195 288 
EGFL7 miR-4289 4  LRP1 miR-4307 188  SDCCAG8 miR-4309 20 
EGFL7 miR-1204 301  LRP1 miR-4472 99  SLIT3 miR-4507 61 
EPCAM miR-4456 112  MCM7 miR-4289 453  SLIT3 miR-4466 253 
EPCAM miR-4492 137  MTUS1 miR-3195 141  SLIT3 miR-4481 314 
EPCAM miR-4508 140  NR2F2 miR-4443 556  SPATA13 miR-4279 12 
HDAC4 miR-3195 266  NR2F2 miR-1538 289  - - - 
 
 
 
Table 2. Positions of ig-miRNA binding sites in CDS mRNA. 
 
Target gene miRNA Position (nt)  Target gene miRNA Position (nt)  Target gene miRNA Position (nt) 
AATK miR-1538 1339  EPHB2 miR-4316 1293  LRP1 miR-4266 5093 
AATK miR-3195 1352  EPHB2 miR-4466 1334  LRP1 miR-4283 12932 
AATK miR-4265 3143  ERBB4 miR-4443 1940  LRP1 miR-4455 12015 
AATK miR-4472 1684  EVL miR-3180 816  LRP1 miR-4456 2930 
AATK miR-4492 3345  EVL miR-4711-3p 802  LRP1 miR-4472 13015 
AATK miR-4711-3p 2715  FOXP1 miR-320d 2225  LRP1 miR-4472 11274 
AKT2 miR-4492 1370  FOXP1 miR-1279 2111  LRP1 miR-4472 2781 
ANTXR1 miR-3141 2010  FOXP1 miR-4264 2506  MAP2K4 miR-4472 120 
ANTXR1 miR-4711-3p 1772  FOXP1 miR-4266 1126  MAP7D2 miR-4417 1395 
BBC3 miR-3665 410  FOXP1 miR-4327 2392  MCM7 miR-4483 1975 
BBC3 miR-4278 884  FOXP1 miR-4736 1146  MRE11A miR-302f 852 
BBC3 miR-4466 319  GIPR miR-659 1441  MRE11A miR-520e 693 
BBC3 miR-4483 744  HDAC4 miR-302e 2082  NOTCH1 miR-516a-3p 6964 
BBC3 miR-4710 796  HDAC4 miR-1205 976  NOTCH1 miR-516b* 6964 
BCAS1 miR-4307 871  HDAC4 miR-4472 2159  NOTCH1 miR-4283 1245 
BID miR-596 364  HDAC4 miR-4481 1868  NOTCH1 miR-4455 6381 
BIRC7 miR-4456 372  HDAC4 miR-4483 2802  NOTCH1 miR-4455 6997 
BRE miR-3201 878  HDAC4 miR-4746-3p 982  NOTCH1 miR-4472 4308 
CCAR1 miR-4463 841  HNF4A miR-1204 278  NOTCH1 miR-4472 7474 
CCAR1 miR-548ak 3272  HNF4A miR-4456 465  NOTCH1 miR-4736 75 
CDH13 miR-4455 2032  HUWE1 miR-320c 3048  PRKG1 miR-599 2933 
DCC miR-1207-3p 3190  HUWE1 miR-320d 3050  PTPRJ miR-4472 2750 
DCC miR-4318 1684  HUWE1 miR-1279 10486  SLIT3 miR-302e 3310 
DCC miR-4325 2917  HUWE1 miR-4264 6886  SLIT3 miR-302f 3310 
DCC miR-4711-3p 3297  HUWE1 miR-4307 3373  SLIT3 miR-4472 3745 
DMD miR-4282 2958  HUWE1 miR-4443 4959  SLIT3 miR-4481 4872 
DMD miR-4493 5132  HUWE1 miR-4792 10624  SLIT3 miR-4492 1201 
DMD miR-4520a-5p 1878  IGF1R miR-1268 1535  SLIT3 miR-4508 1201 
DMD miR-4520b-5p 1878  IGF1R miR-4282 528  SLIT3 miR-4513 499 
DMD miR-4650-5p 5135  IGF1R miR-4456 462  SPATA13 miR-1261 1854 
DNMT3A miR-302f 3075  LFNG miR-1274b 175  SPATA13 miR-4266 2070 
DNMT3A miR-665 1570  LFNG miR-3195 178  SPATA13 miR-4456 2864 
DNMT3A miR-3676 1221  LFNG miR-4264 1154  TNKS miR-4455 3891 
DNMT3A miR-4456 2223  LRP1 miR-132 4503  TNKS miR-4465 1769 
EIF4H miR-645 705  LRP1 miR-1261 7704  TNKS miR-4531 647 
EPHB2 miR-4253 1087  LRP1 miR-4253 10550  - - - 
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Table 3. Positions of ig-miRNA binding sites in 3'UTR mRNA. 
 
Target gene miRNA Position (nt)  Target gene miRNA Position (nt)  Target gene miRNA Position (nt) 
AATK miR-4472 4514  EPHB2 miR-4455 4792  IGF1R miR-4455 8927 
AKT2 miR-4316 2472  ERBB4 miR-4279 10500  IGF1R miR-769-3p 7824 
AKT2 miR-4418 3951  ERBB4 miR-568 11012  IGF1R miR-4455 10709 
AKT2 miR-4264 2336  ERBB4 miR-3123 4973  LFNG miR-466 1269 
BBC3 miR-4507 1000  ERBB4 miR-302f 5163  LFNG miR-4318 1899 
BBC3 miR-4505 1000  ERBB4 miR-513a-5p 4123  LRP1 miR-4328 14372 
BBC3 miR-4497 965  FBXW7 miR-3674 3468  MAP2K4 miR-1827 3050 
BBC3 miR-3676 1616  FOXP1 miR-466 5945  MCM7 miR-4466 2782 
BBC3 miR-1587 1000  FOXP1 miR-4266 3217  MRE11A miR-4456 3832 
BBC3 miR-4279 1636  HDAC4 miR-4478 8388  MTUS1 miR-513a-5p 4652 
BID miR-543 2428  HDAC4 miR-4529-5p 6541  MTUS1 miR-4443 6051 
BRE miR-4456 1575  HDAC4 miR-4482 7344  MTUS1 miR-3168 4674 
CDH13 miR-297 3603  HDAC4 miR-4710 8162  MTUS1 miR-513b 4652 
DCC miR-302f 6493  HDAC4 miR-4311 7024  NOTCH1 miR-1587 8133 
EGFL7 miR-3130-5p 1454  HDAC4 miR-4328 4662  NOTCH1 miR-1275 9070 
EIF4H miR-4309 1364  HNF4A miR-3934 1350  SPATA13 miR-876-3p 6126 
EIF4H miR-197 1627  IGF1R miR-4456 7101  - - - 
 
 
 
had six miRNA binding sites in 3'UTR and three of them 
were located in same place (miR-4505, miR-4507 and 
miR-1587). Such part of mRNA is very important for its 
regulation via several miRNA. 
 
 
Interaction of intronic miRNAs with mRNAs genes 
coding in-miRNA 
 
Oncogenes (51) are host genes and target genes for in-
miRNAs. Majority of these in-miRNAs are encoded in 
intron. Five of the studied genes (ATF2, BID, DMD, EVL 
and FOXP1) encode intronic pre-miRNAs in their 3'UTRs 
and another five genes (BBC3, EPHB2, NR2F2, PTPRJ 
and SPATA13) in their 5'UTRs. Some genes encode one 
or more in-miRNA. For example, AATK gene encodes 
pre-miR-338, pre-miR-657 and pre-miR-1250; HDAC4 
gene encodes pre-miR-2467, pre-miR-4440 and pre-miR-
4441.  
Binding sites of 686 in-miRNAs with 51 mRNAs were 
studied (Table 4). The miRNA binding sites number are 
significantly different for the studied mRNAs. All parts of 
the studied mRNAs have similar binding ability to miRNA. 
In-miRNAs shares were 20.9, 39.5 and 39.5% sites in 
5'UTR, CDS, 3'UTR, respectively. The average binding 
sites densities of 5'UTR, CDS and 3'UTR computed 
mRNAs were 1.81, 0.61 and 0.73 s/l, respectively. These 
results indicate that miRNAs can bind to 5'UTR, CDS and 
3'UTR. LRP1 gene has six miRNA binding sites in all 
parts of its mRNA: 5'UTR (miR-4274), CDS (miR-1273f, 
miR-4295, miR-4296 and miR-500b) and 3'UTR (miR-
4297). HUWE1 gene has miRNA binding sites (miR-
4297, miR-548an and miR-598) only in CDS and LFNG 
gene had sites (miR-1224-3p, miR-500b) only in 3'UTR. 
Some mRNAs can be targets to in-miRNAs that encode 
in different pre-mRNA genes.  
The linkages between genes via in-miRNAs are 
presented in Table 4. Some of the studied mRNAs belong 
to the host and target genes. For example, BIRC7 
encode in-miR-3196 and is target for in-miR-4292, in-
miR-4257 and ig-miR-4456 at the same time. IGF1R 
gene is target for miR-1268B (CCDC40), miR-1273F 
(SCP2), miR-3173 (DICER1), miR-361 (CHM), miR-4292 
(C9orf86), and miR-4297 (EBF3), where gene origin 
corresponding pre-miRNA is shown in brackets. These 
data show a linkage between different oncogenes 
encoded intronic miRNAs, where each mRNA is target for 
some miRNAs and encodes other miRNAs. 
 
 
Interaction of exonic miRNAs with mRNA genes 
coding in-miRNA 
 
Binding sites of 49 ex-miRNAs with 51 mRNAs have 
been studied. The linkages between genes via ex-
miRNAs are presented in Table 5. Despite the small 
number of target genes, these data have proved that ex-
miRNA can bind to CDS and 3'UTR, but there is no site in 
5'UTR. Only seven out of all ex-miRNAs interact with 
seven target mRNAs. Shares of binding sites for ex-
miRNAs were 75% sites in CDS and 25% sites in 3'UTR 
of mRNA.  DMD gene had two miRNA binding sites (miR-
4315 and miR-1306). miR-4315 has two target genes 
(DMD and BIRC6). DNMT3A gene encodes in-miR-1301 
and is a target for ex-miR-4775. These data show a 
linkage between host genes of exonic and intronic 
miRNA. 
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Table 4. Positions of in-miRNA binding sites in 5'UTR, CDS, 3'UTR mRNA. 
 
Target gene miRNA Position (nt) Host gene 
5'UTR    
BIRC7 miR-4292 60 C9orf86 
EPCAM miR-4317 45 L3MBTL4 
EPCAM miR-4753-3p 7 ARID4B 
GIPR miR-26a-1* 25 CTDSPL 
HDAC4 miR-1268b 78 CCDC40 
HDAC4 miR-1914* 540 UCKL1 
HDAC4 miR-4296 53 CTBP2 
HDAC4 miR-4296 159 CTBP2 
IGF2 miR-1273f 81 SCP2 
LRP1 miR-4274 428 SORCS2 
PRKG1 miR-1268b 140 CCDC40 
PTPRJ miR-1238 208 ATG4D 
    
CDS    
AATK miR-4651 4029 POR 
ABCA6 miR-3941 3053 PLEKHA1 
BBC3 miR-4655-3p 598 MAD1L1 
BID miR-4285 432 SH2B2 
BIRC7 miR-4257 745 ADAMTSL4 
BRE miR-4259 315 CCDC19 
DMD miR-4753-3p 11190 ARID4B 
DNMT3A miR-593 674 SND1 
ERBB4 miR-3182 3863 CDH13 
ERBB4 miR-4797-3p 3376 DLG1 
EVL miR-1322 522 PINX1 
EVL miR-4281 1001 SNCB 
GIPR let-7g 140 WDR82 
GIPR miR-1238 182 ATG4D 
LRP1 miR-500b 1824 CLCN5 
LRP1 miR-1273f 3301 SCP2 
LRP1 miR-4295 6360 VTI1A 
NOTCH1 miR-1271 1240 ARL10 
NOTCH1 miR-3196 688 BIRC7 
PTPRJ miR-342-5p 459 EVL 
SLIT2 miR-4446-3p 4223 SIDT1 
SLIT3 miR-500b 426 CLCN5 
SPATA13 miR-652 482 TMEM164 
    
3'UTR    
AATK miR-648 4498 MICAL3 
AKT2 miR-3196 1865 BIRC7 
AKT2 miR-4281 2711 SNCB 
ANTXR1 miR-32* 5217 C9orf5 
BBC3 miR-3156-3p 1667 ANKRD30B 
CDH13 miR-574-5p 3603 FAM114A1 
EBF3 miR-500b 2252 RPS6KA1 
EBF3 miR-1976 2260 CLCN5 
EGFL7 miR-3130-5p 1454 FASTKD2 
EIF4H miR-4263 1611 BRE 
ERBB4 miR-483-3p 10500 IGF2 
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Table 4. Continued. 
 
ERBB4 miR-877* 10504 ABCF1 
HDAC4 miR-1289 6515 FSTL4 
HDAC4 miR-4326 4606 ARFGAP1 
IGF1R miR-361-3p 7089 CHM 
IGF1R miR-1273f 7624 SCP2 
IGF1R miR-3173-5p 5679 DICER1 
IGF1R miR-4292 6166 C9orf86 
IGF2 miR-1273f 1902 SCP2 
IGF2 miR-3972 4533 PADI3 
IGF2 miR-4263 3055 BRE 
IGF2 miR-4296 4307 CTBP2 
LFNG miR-1224-3p 2007 VWA5B2 
 
 
 
Table 5. Positions of ex-miRNA binding sites in CDS, 3'UTR mRNA. 
 
Target gene miRNA Position (nt) Host gene 
CDS    
BIRC6 miR-4315 11064 PLEKHM1 
BIRC7 miR-1825 373 POFUT1 
DMD miR-4315 6086 PLEKHM1 
DMD miR-1306 2819 DGCR8 
GIPR miR-671-5p 1236 CHPF2 
HUWE1 miR-3652 6967 HSP90B1 
    
3'UTR    
DNMT3A miR-4775 3420 CCNYL1 
MTUS1 miR-1306 5360 DGCR8 
 
 
 
HDAC4 mRNA has three types of miRNA binding 
sites 
 
As it is known, there exist three types of binding sites: 5'-
dominant canonical, 5'-dominant seed only and 3'-
compensatory sites (Betel et al., 2010). Canonical site 
has good (or perfect) complementarity at both the 5'- and 
3'-ends of the miRNA with a specific bulge in the middle. 
Dominant seed site has perfect seed 5'-complementarity 
to the miRNA but poor 3'-complementarity. Compensatory 
site has a mismatch (wobble) in the 5'-seed region, but 
compensate through excellent complementarity at the 3'-
end of miRNA. 
5'-dominant canonical and 3'-compensatory types of 
binding sites were found in the obtained data. There is no 
5'-dominant seed of binding sites, because such sites 
have low energy of binding site and are not reliable 
according to our criteria. In addition, complementary type 
of miRNA binding sites was found after the analysis of our 
results. It has perfect complementarity beginning with 
second nucleotide and completing the last but one 
nucleotide of miRNA in binding site. There was no bugle 
in the middle (Table 6). Such binding sites have high 
energy of binding site and are reliable according to our 
criteria. 
HDAC4 mRNA had three types of miRNA binding sites. 
For example, 5'-dominant canonical sites were in-miR-
4296 and ig-miR-3195; 3'-compensatory sites were ig-
miR-4311 and in-miR-1914*; complementary sites were 
ig-miR-4478 and in-miR-1289 (Table 6). Main contribution 
to energy can include all parts of miRNA site, but not only 
5'seed. HDAC4 mRNA is a target for several intergenic 
and intronic miRNAs. In both cases, sites may be found 
in any region mRNA. The sites found have high 
hybridization energy due to significant amount of 
complementary nucleotides. 
 
 
DISCUSSION 
 
Expression may be regulated by miRNAs for more than a 
half of human genes (Friedman et al., 2009). The number 
of known human miRNAs constantly increases, as well as 
the number of their potential target genes. The 
establishment of target genes depends on the efficiency 
of their prediction by computer methods. Indeed, 
experimental verification of predicted target genes 
depends on the  accuracy  of  prediction  of  miRNA  sites  
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Table 6. Schematic representation of types of miRNA bindings sites in mRNA HDAC4. 
 
5'UTR,53   ΔG=-33,5  ΔG/ΔGm=84    5'-d/c  5'UTR,266   ΔG=-38,8  ΔG/ΔGm=84   5'-d/c 
   
mRNA       5' CGAGCCCGAGCCCGCGC 3'    
miR-4296  3' ACUCGGACUCGGGUGUA 5' 
 
MRNA       5' AGCCCCGGCCCGGCGCC 3'  
miR-3195  3' UUGGGCCCGGGCCGCGC 5' 
   
3'UTR,7024  ΔG=-28,8  ΔG/ΔGm=80   3'-compn.  5'UTR,540   ΔG=-46,8  ΔG/ΔGm=81   3'-compn. 
   
mRNA       5' CACACUCGGCUCUUCUCC 3'   
miR-4311  3' GUGUGAGUCGAGAGAAAG 5'  
 
MRNA       5' UCUCCCGGUGCGGGGCCCGCGCC 3'      
miR-1914* 3' GGAGGGUCACGCCCUGGG-GAGG  5'                         
   
3'UTR,8388  ΔG=-34,6  ΔG/ΔGm=87   compl.   3'UTR,6515  ΔG=-36,7  ΔG/ΔGm=80   compl.   
   
mRNA       5' GUUCUUAGCUCGGCCUC 3'  
miR-4478  3' GAGGAGUCGAGUCGGAG 5'  
 
mRNA       5' UGAGUGCAGAUUCUUGGAUUCAC 3' 
miR-1289  3' UUUUACGUCUAAGGACCUGAGGU 5'             
 
Interaction energy (ΔG) is measured in kcal/mol. The ΔG/ΔGm value is calculated in percents. Types of binding sites: 5'-d/c – 5'-
dominant canonical, 3'-comp. – 3'-compensatory,  compl. – complementary site. 
 
 
 
and their characteristics considered in corresponding 
programs. Besides, the essential role of prediction of 
binding sites and their validation have limitation 
depending on the quality of prediction (Grimson et al., 
2007). Functional regions of mRNAs were shown to be 
significantly heterogeneous according to the number of 
binding sites and to the location density of these miRNA 
sites (Issabekova et al., 2011).  
In our work, interaction sites of 1519 miRNAs with 51 
mRNA-targets are presented. Majority of these miRNAs 
were revealed recently (with miRNA index number 1000 
and more) and were bad-studied. Total number of miRNA 
binding sites was found in the studied target genes to be 
439. Some miRNAs have several binding sites with the 
same mRNA. Average number of binding sites was six 
miRNAs on mRNA. miRNA sites with high ΔG/ΔGm ratio 
were selected with P < 0.0004. In-miRNAs and ig-
miRNAs have similar properties. miRNAs with length 22 
nt have distinct prevalence concerning others which have 
bigger or smaller length. A great number of in-miRNAs 
and ig-miRNAs have a high GC-content (50 to 55%). 
Most genes under study appear to have binding sites with 
miRNA. Therefore, it is possible that the expression of a 
significant part of human genes is under a regulation 
control by miRNAs. Intergenic miR-4472, miR-4456, miR-
4455, miR-302f and miR-3195 had thirteen, nine, seven, 
six and five target genes accordingly. The expression of 
such miRNAs can repress translation of some genes 
participating in cancer development. 
The shares of all binding sites (18.4, 58.2 and 23.4%) 
in 5'UTR, CDS, 3'UTR of the studied mRNA, respectively 
were found. Ig-miRNA binding sites were in 3.3 times 
more than it is to ig-miRNA. Thus, the density of binding 
sites in 5'UTR was 2.6 times more than it was in CDS 
and 2.8 times more than it was in 3'UTR. Such data 
indicate that miRNAs can interact with 5'UTR and CDS, 
and not only with 3'UTR. Some miRNAs have a high site 
density in 5'UTR. A significant part of the studied miRNAs 
interacts with mRNA of only one gene. Effect on such 
miRNAs would allow selection of modification of 
associated target genes expression. mRNAs of some 
genes are targets for ig-miRNAs and in-miRNAs. Majority 
intronic and exonic miRNAs express together with their 
host genes. These miRNA provide interaction of 51 host 
genes of in-miRNA with other host genes via in-miRNAs 
and ex-miRNAs. Changes in host gene expression lead 
to changes of intronic and exonic miRNA expression. 
These processes influence the target genes translation. 
 
 
Conclusion 
 
Computational prediction of miRNA binding sites is an 
important stage in the investigation of biological function 
miRNA. These data promote understanding the features 
of gene regulation on post-transcription level via miRNAs. 
The linkage between different genes encoding in-miRNAs 
and being targets for in-miRNAs was revealed. These 
genes participate in different cellular processes and 
reveal linkages between such genes participating in 
gastrointestinal cancer. 
It was found that the percentage of ig-miRNA, ex-miRNA 
and in-miRNA sites are approximately identical in 5'UTR,  
 
 
 
 
CDS, and 3'UTR. Approximately 2/3 of these sites bind to 
5'UTR or CDS regions. This suggests that sites involved 
in a translation regulation by miRNAs are located not only 
in 3'UTR, but in 5'UTR and CDS regions.  
According to these data, nearly 45% of miRNAs are 
intronic and their synthesis directly depends on 
transcription of corresponding host genes. In-miRNAs 
had no strong binding to mRNAs of the 51 studied 
oncogenes. Therefore, in-miRNAs do not inhibit the 
expression of host genes.  
Three types of schemes of interaction between mRNA 
and miRNA was revealed. There were 5'-dominant 
canonical sites, 3'-compensatory sites and 
complementary sites. The primary contribution to energy 
can include not only 5'seed, but all the parts of miRNA 
site. Hence, all the parts of miRNA sites can bring 
contribution to the total energy of binding site (ΔG/ΔGm). 
High miRNA concentration, that reduce expression of 
gene-suppressors can be identiec to stimulation of 
carcinogenesis. The effect of low miRNA concentration 
on oncogenes can cause the development of cancer. 
Changes that occur in miRNA concentration can possibly 
be used as medicines in anti-sense therapy of breast and 
gastrointestinal tract cancer. 
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APPENDIX 
 
Supplementary Table 1. Fifty-0ne (51) Oncogenes coding intronic miRNAs. 
 
Gene Full name of gene References 
AATK Apoptosis-associated tyrosine kinase Lee et al. (2006)  
ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 Hlavata et al. (2012)  
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 Hlavata et al. (2012) 
AKT2 V-akt murine thymoma viral oncogene homolog 2 Li et al. (2011) 
ANTXR1 Anthrax toxin receptor 1 Rmali et al. (2004) 
ATF2 Activating transcription factor 2 Asting et al. (2011) 
BBC3 BCL2 binding component 3 Ray et al. (2011)  
BCAS1 Breast carcinoma amplified sequence 1 Correa et al. (2000)  
BID BH3 interacting domain death agonist Ma et al. (2012) 
BIRC6 Baculoviral IAP repeat-containing 6 Van et al. (2011)  
BIRC7 Baculoviral IAP repeat containing 7 Oh et al. (2011) 
BRE Brain and reproductive organ-expressed  Yao et al. (2012)  
CCAR1 Cell division cycle and apoptosis regulator 1 Ou et al. (2009)  
CDH13 Cadherin 13, H-cadherin (heart) Hibi et al. (2004) 
DCC Deleted in colorectal carcinoma  Derks et al. (2009) 
DMD Dystrophin Edward et al. (2004) 
DNMT3A DNA (cytosine-5-)-methyltransferase 3 alpha Schneider-Stock et al. (2005) 
DTL Denticleless homolog (Drosophila) Baraniskin et al. (2012) 
EBF3 Early B-cell factor 3 Kim and Kim (2007) 
EGFL7 EGF-like-domain, multiple 7 Díaz et al. (2008) 
EIF4H Eukaryotic translation initiation factor 4H Wu et al. (2011)   
EPCAM Epithelial cell adhesion molecule Tao et al. (2012)  
EPHB2 EPH receptor B2 Herath et al. (2012)  
ERBB4 V-erb-a erythroblastic leukemia viral oncogene homolog 4  Frey et al. (2010) 
EVL Enah/Vasp-like Yi et al. (2011) 
FBXW7 F-box and WD repeat domain containing 7 Milne et al. (2010) 
FOXP1 Forkhead box P1 Adams et al. (2009) 
GIPR Gastric inhibitory polypeptide receptor Prabakaran et al. (2010) 
HDAC4 Histone deacetylase 4 Jin et al. (2012) 
LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase Reedijk et al. (2008).  
HNF4A Hepatocyte nuclear factor 4, alpha Weltmeier et al. (2011) 
HUWE1 HECT, UBA and WWE domain containing 1 Zhao et al. (2008) 
IGF1R Insulin-like growth factor 1 receptor Pennarun et al. (2011) 
IGF2 Insulin-like growth factor 2 (somatomedin A) Hoyo et al. (2012) 
LRP1 Low density lipoprotein receptor-related protein 1 Toquet et al. (2007) 
MAP2K4 Mitogen-activated protein kinase kinase 4 Soh et al. (2001)  
MAP7D2 MAP7 domain containing 2 Sjöblom et al. (2006) 
MCM7 Minichromosome maintenance complex component 10 Nishihara et al. (2009) 
MRE11A MRE11 meiotic recombination 11 homolog A (Saccharomyces cerevisiae) Takemura et al. (2006) 
MTUS1 Microtubule associated tumor suppressor 1 Zuern et al. (2010) 
NOTCH1 Notch 1p Zhang et al. (2010) 
NR2F2 Nuclear receptor subfamily 2, group F, member 2 Corneza et al. (2008) 
PRKG1 Protein kinase, cGMP-dependent, type I Savas et al.  (2010) 
PTK2 PTK2 protein tyrosine kinase 2 Leve et al. (2011) 
PTPRJ Protein tyrosine phosphatase, receptor type, J Jeon et al. (2009) 
SDCCAG8 Serologically defined colon cancer antigen 8 Kamio et al. (2010) 
SLIT2 Slit homolog 2 (Drosophila) Li-F et al. (2012) 
SLIT3 Slit homolog 3 (Drosophila) Zhu et al. (2011) 
SPATA13 Spermatogenesis associated 13 Kawasaki et al. (2007) 
TNFAIP6 Tumor necrosis factor, alpha-induced protein 6 Hamm et al. (2008) 
TNKS TRF1-interacting ankyrin-related ADP-ribose polymerase Shebzukhov et al. (2008) 
 
